Literature DB >> 8847866

Bradykinin B2 receptor involvement in rabbit and murine models of septic shock.

M Félétou1, I Jamonneau, M Germain, C Thurieau, J L Fauchère, P Villa, P Ghezzi, E Canet.   

Abstract

The purpose of our work was to evaluate the role of bradykinin B2 receptors in the early phase (first 3 h) of bacterial lipopolysaccharide (LPS)-induced shock in anesthetized and mechanically ventilated rabbits and to determine if HOE 140, a specific, potent, and long-acting bradykinin B2-receptor antagonist, could improve survival in two murine models of septic shock. In rabbits, LPS injection induced rapid hypotension associated with metabolic acidosis. Three hours after the injection of LPS, we observed leukopenia, thrombocytopenia, and a moderate increase in arterial blood cyclic GMP. The injection-of HOE 140 [1.7-mumol/kg bolus intravenously (i.v.) 20 min before LPS] inhibited the decrease in blood pressure, but did not influence any of the other parameters studied. Mice were subjected to intraperitoneal (i.p.) injection of LPS, which induced almost 100% mortality in the 4 days after the injection. Pretreatment with HOE 140 (1 mg/kg i.p.) 30 min before the LPS injection and 4, 8, and 24 h afterward the injection did not improve survival at any given time during the 4 days of the study. Cecal ligation and puncture in mice induced a mortality rate > 90% in < or = 10 days. HOE 140 (1 mg/kg i.v.) given 30 min before cecal ligation did not significantly improve the survival rate. In contrast with previous reports, in the present study in a rabbit model of endotoxic shock (early phase) and in two murine models of septic shock, the involvement of bradykinin B2 receptors appeared to be minimal.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8847866     DOI: 10.1097/00005344-199604000-00008

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

Review 1.  C1 inhibitor: biologic activities that are independent of protease inhibition.

Authors:  Alvin E Davis; Shenghe Cai; Dongxu Liu
Journal:  Immunobiology       Date:  2006-12-11       Impact factor: 3.144

Review 2.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

Review 3.  Kinin receptors.

Authors:  F Marceau; D R Bachvarov
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  PF-04886847 (an inhibitor of plasma kallikrein) attenuates inflammatory mediators and activation of blood coagulation in rat model of lipopolysaccharide (LPS)-induced sepsis.

Authors:  D Kolte; J W Bryant; G W Gibson; J Wang; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2012-06

Review 5.  Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors.

Authors:  F Kuhr; J Lowry; Y Zhang; V Brovkovych; R A Skidgel
Journal:  Neuropeptides       Date:  2010-01-04       Impact factor: 3.286

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.